HCOVID-19 has been announced a widespread by the world wellbeing organization. Patients with cancer, and especially hematologic malignancies may be at higher hazard for extreme complications due to their harm, safe dysregulation, treatment, and related comorbidities. The oncology community has been proactive in issuing hone rules to assist optimize administration, and restrain disease hazard and complications from SARSCOV- 2. In spite of the fact that hematologic malignancies account for as it were 10% of all cancers, their administration is particularly complex, particularly within the time of COVID-19. Screening or early discovery of COVID-19 are central for preventative/mitigation methodology, which is the most excellent current methodology in our fight against COVID-19. In this, we offer an outline of COVID-19 screening procedures and highlight the interesting perspectives of treating patients with hematologic malignancies.
